Telix Pharmaceuticals (ASX:TLX): Quarterly Revenue, Imaging Products and Clinical Programs

Aditi Sarkar

22 October 2026 04:20 PM AEDT

Telix Pharmaceuticals (ASX:TLX): Quarterly Revenue, Imaging Products and Clinical Programs

Image Source: Shutterstock

You are reading a free article with opinions that may differ from the recommendation given by Kalkine in its paid research reports. Become a Kalkine member today to get access to our research reports, in-depth technical and fundamental research. Learn more

Start Your Free Trial Now!

Highlights

Telix Pharmaceuticals (ASX:TLX) reported Q3 2026 group revenue of US$245 million, up 19% year on year.
Precision Medicine contributed US$201 million in quarterly revenue, increasing 30% year on year.
The company maintained FY26 revenue guidance of US$950–970 million and revised its research spending range.
Pixclara entered U.S. commercial use, while several clinical and regulatory programs progressed.

Telix Pharmaceuticals Limited develops and commercialises diagnostic and therapeutic radiopharmaceuticals and associated medical technologies for cancer care. The Australian-listed business operates commercial imaging services alongside clinical-stage therapeutic programs, with the United States central to its commercial operations. On 22 October 2026, Telix Pharmaceuticals (ASX:TLX) was quoted at AUD 13.97, down 3.79% in the trading figures for the day. Its latest quarterly update, released on 21 October, reported growth in group revenue and outlined developments across its imaging portfolio, manufacturing network and clinical pipeline.

Company Business

Telix operates through Precision Medicine and Telix Manufacturing Solutions (TMS), while advancing a separate portfolio of investigational cancer treatments. Its approved prostate cancer imaging products include Illuccix and Gozellix, which use prostate-specific membrane antigen targeting for positron emission tomography (PET). Pixclara is a U.S.-approved PET imaging agent for glioma. The group also develops kidney cancer imaging, treatments for prostate and brain cancers, and radiopharmaceutical manufacturing technologies.

In its September-quarter update, Telix Pharmaceuticals (ASX:TLX) reported that TMS encompasses radiopharmacy operations and isotope-production technology. The RLS network supports the preparation and distribution of radiopharmaceutical products in the United States. Commercial product approvals and geographical availability vary by medicine; several candidates in the clinical pipeline have not received marketing authorisation.

Recent Development

During October 2026, Telix confirmed the initial commercial administration of Pixclara in the United States at centres in Cleveland and Indianapolis. Its Phase 3 BiPASS study of prostate imaging before biopsy completed enrolment of 350 patients, and the U.S. Food and Drug Administration granted Fast Track designation to the program. Telix also continued preparatory work for a U.S. regulatory resubmission relating to its kidney cancer imaging candidate Zircaix, following manufacturing-related agency observations.

Telix Pharmaceuticals (ASX:TLX) also announced an October collaboration with Ekalia concerning the U.S. production of astatine-211, an isotope under investigation for targeted alpha therapy. The arrangement includes a proposed alpha-beam cyclotron installation at an RLS facility near Philadelphia. Separately, a proposed merger with Isotope Technologies Munich was announced in September, with completion subject to shareholder approval and other conditions. The stated upfront consideration is US$1.65 billion on a cash-free, debt-free basis, including approximately US$1.25 billion in Telix shares for ITM shareholders.

Financial Performance and Sector Context

For the quarter ended 30 September 2026, Telix reported unaudited group revenue of US$245 million, compared with US$206 million in Q3 2025, an increase of 19%. Precision Medicine revenue rose to US$201 million from US$155 million, representing growth of 30%. TMS revenue was US$44 million compared with US$47 million, a decline of 6%. Group revenue was 1% below the US$247 million recorded in Q2 2026.

For H1 2026, Telix Pharmaceuticals (ASX:TLX) reported group revenue of US$477 million, up 22% year on year. The gross margin was 55%, compared with 53% a year earlier. Adjusted EBITDA was US$52 million, a 146% increase, with the result including an initial non-refundable US$40 million payment from a research collaboration. Research and development spending reached US$124 million in the half-year. Adjusted EBITDA is a non-statutory performance measure and is not equivalent to net profit.

The company retained FY26 revenue guidance of US$950 million to US$970 million, indicating performance toward the upper end of that range. With US$40 million in other income, the company expects combined revenue and other income to exceed US$1 billion. It narrowed expected FY26 research and development expenditure to US$240 million–US$260 million from US$230 million–US$270 million. The radiopharmaceutical sector depends on regulatory approvals, access to medical isotopes and reliable time-sensitive manufacturing and distribution.

Risks to Consider

Telix Pharmaceuticals (ASX:TLX) faces clinical trial, product approval and manufacturing execution risks. Any delay in regulatory review could alter commercialisation schedules, while radioisotope supply constraints can affect product availability. The proposed ITM transaction carries approval, financing and integration considerations. Higher development expenditure, competition in imaging diagnostics and dependence on reimbursement arrangements also affect operating conditions.

What to Watch Next

Near-term monitoring points include the proposed ITM transaction approvals, the Zircaix regulatory resubmission, adoption of Pixclara and execution against FY26 revenue and expenditure guidance. The company has indicated that results from the OPTIMAL-PSMA Phase 2 study are expected during the first half of 2027. Updates on ProstACT, BiPASS and additional radiopharmacy installations will provide further information on clinical and operational progress.

Key Insights

Telix Pharmaceuticals (ASX:TLX) reported year-on-year quarterly revenue growth, supported by Precision Medicine, while TMS revenue declined. Its revised research expenditure range accompanies ongoing work in therapeutics, diagnostics and manufacturing. The principal observable developments are commercial product uptake, clinical milestones, regulatory decisions and execution of the proposed merger.

Download Free Report – Explore 3 Stock Ideas & Industry Insights

Unlock 3 stock ideas and key industry insights in our free report. This information is general in nature and does not consider your personal objectives, financial situation, or needs. It is not financial advice.

All investments involve risk—consider independent advice before making any investment decisions.

View 3 Research Reports

Disclaimer:

This article (“Article”) has been prepared by Kalkine Pty Limited (ABN 34 154 808 312) (Australian financial services licence number 425376) (“Kalkine”) and its related bodies corporate who are authorised to provide general financial product advice. Kalkine.com.au and its associated pages are published by Kalkine.

Any information/advice provided in this article is general in nature and does not take into account your objectives, financial situation or needs. You should therefore consider whether the information is appropriate for your objectives, financial situation and needs before acting upon it.

There may be a Product Disclosure Statement, Information Memorandum or other offer document (“Offer Document”) for the securities or other financial products referred to in Kalkine articles. You should obtain a copy of the Offer Document and consider it before making any decision about whether to acquire the security or financial product.

Kalkine strongly recommends that you seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice) before acting on any advice/information in this Article or on the Kalkine website. Not all investments are appropriate for all people.

The information in this Article and on Kalkine website has been prepared from a wide variety of sources, which Kalkine, to the best of its knowledge and belief, considers accurate. Kalkine has made every effort to ensure the reliability of the information contained in its articles (including this Article), newsletters and websites. All information represents our views at the date of publication and may change without notice.

The information in this Article does not constitute an offer to sell securities or other financial products or a solicitation of an offer to buy securities or other financial products.

Kalkine does not issue, sell or deal in any financial products.

This Article may contain information on past performance of particular investments. Please note past performance is neither an indicator nor a guarantee of future performance.

To the extent permitted by law, and excluding any dishonesty or gross negligence by Kalkine, Kalkine disclaims and excludes all liability for any direct, indirect, implied, punitive, special, incidental or other consequential loss or damage arising from the use of or reliance on this Article, the Kalkine website and any information published on the Kalkine website without any warranties or representations by Kalkine to you. To the extent the law prohibits or limits this exclusion, Kalkine limits its liability to the resupply of services.

Please also read our Terms & Conditions and Financial Services Guide for further information.

Employees and/or associates of Kalkine and its related entities may hold interests in the securities or other financial products covered in this Article or on the Kalkine website. Any such employees and associates are required to comply with certain safeguards, procedures and disclosures as required by law.

Some of the images/music that may be used in the Article are copyright to their respective owner(s). Kalkine does not claim ownership of any of the pictures displayed/music used in the Article unless stated otherwise. The images/music that may be used in the Article are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have used reasonable efforts to accredit the source wherever it was indicated or was found to be necessary.

Kalkine Media Pty Ltd, an affiliate of Kalkine Pty Ltd, may have received, or be entitled to receive, financial consideration in connection with providing information about certain entity(s) covered on its website.